Cidara Therapeutics (CDTX)
(Delayed Data from NSDQ)
$12.63 USD
-0.37 (-2.85%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $12.59 -0.04 (-0.32%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CDTX 12.63 -0.37(-2.85%)
Will CDTX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CDTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CDTX
TELA Bio, Inc. (TELA) Reports Q4 Loss, Tops Revenue Estimates
Emergent Biosolutions (EBS) Reports Q4 Loss, Tops Revenue Estimates
CDTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Codexis (CDXS) Tops Q4 Earnings and Revenue Estimates
Cidara (CDTX) Up on EC Nod for Rezzayo in Invasive Candidiasis
GSK (GSK) Q3 Earnings and Revenues Surpass Estimates
Other News for CDTX
Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024
Cidara Therapeutics announces presentations on CD388 data
Cidara Therapeutics: Now Well-Funded To Advance Its Cloudbreak Platform
MiMedx Group, Cyclacel Pharmaceuticals, Predictive Oncology among healthcare movers
Mimedx Group, Cyclacel Pharmaceuticals, Predictive Oncology among healthcare movers